Simvastatin is protective during staphylococcus aureus pneumonia

Current Pharmaceutical Biotechnology

Volumn 12, Issue 9, 2011, Pages 1455-1462

  Mcdowell, Susan A ^a   Ma, Yan ^b   Kusano, Ryosuke ^b,c   Akinbi, Henry T ^b  

^a BALL STATE UNIVERSITY   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Protein c; Simvastatin; Staphylococcus aureus; Statins; Tissue factor

Indexed keywords

PROTEIN C; SIMVASTATIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BACTERIAL CLEARANCE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; MOUSE; NONHUMAN; PROTECTION; STAPHYLOCOCCAL PNEUMONIA; TREATMENT OUTCOME;

ANIMALS; BACTERIAL LOAD; BRONCHOALVEOLAR LAVAGE FLUID; C-REACTIVE PROTEIN; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; PEROXIDASE; PNEUMONIA, STAPHYLOCOCCAL; PROTEIN C; SIMVASTATIN; THROMBOPLASTIN;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

EID: 80052255012     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Neyrinck, A.P.; Liu, K.D.; Howard, J.P.; Matthay, M.A. Protective mechanisms of activated protein C in severe inflammatory disorders. Br. J. Pharmacol., 2009, 158(4), 1034-1047.
2. Miida, T.; Hirayama, S.; Nakamura, Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J. Atheroscler Thromb., 2004, 11(5), 253-264.
3. Liao, J.K. Clinical implications for statin pleiotropy. Curr. Opin. Lipidol., 2005, 16(6), 624-629.
4. Horn, M.P.; Knecht, S.M.; Rushing, F.L.; Birdsong, J.; Siddall, C.P.; Johnson, C.M.; Abraham, T.N.; Brown, A.; Volk, C.B.; Gammon, K.; Bishop, D.L.; McKillip, J.L.; McDowell, S.A. Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J. Pharmacol. Exp. Ther., 2008, 326(1), 135-143.
5. Veltrop, M.H.; Beekhuizen, H.; Thompson, J. Bacterial speciesand strain-dependent induction of tissue factor in human vascular endothelial cells. Infect. Immun., 1999, 67(11), 6130-6138.
6. Heying, R.; van de Gevel, J.; Que, Y.A.; Piroth, L.; Moreillon, P.; Beekhuizen, H. Contribution of (sub)domains of Staphylococcus aureus fibronectin-binding protein to the proinflammatory and procoagulant response of human vascular endothelial cells. Thromb. Haemost., 2009, 101(3), 495-504.
7. Liappis, A.P.; Kan, V.L.; Rochester, C.G.; Simon, G.L. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis., 2001, 33(8), 1352-1357.
8. Almog, Y.; Shefer, A.; Novack, V.; Maimon, N.; Barski, L.; Eizinger, M.; Friger, M.; Zeller, L.; Danon, A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 2004, 110(7), 880-885.
9. Yasuda, H.; Yuen, P.S.; Hu, X.; Zhou, H.; Star, R.A. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int., 2006, 69(9), 1535-1542.
10. Spitzer, A.L.; Harris, H.W. Statins attenuate sepsis. Surgery, 2006, 139(3), 283-287.
11. Kruger, P.; Fitzsimmons, K.; Cook, D.; Jones, M.; Nimmo, G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med., 2006, 32(1), 75-79.
12. Kruger, S.; Merx, M.W. Nonuse of statins--a new risk factor for infectious death in cardiovascular patients? Crit. Care Med., 2007, 35(2), 631-632.
13. Terblanche, M.; Almog, Y.; Rosenson, R.S.; Smith, T.S.; Hackam, D.G. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect. Dis., 2007, 7(5), 358-368.
14. Donnino, M.W.; Cocchi, M.N.; Howell, M.; Clardy, P.; Talmor, D.; Cataldo, L.; Chase, M.; Al-Marshad, A.; Ngo, L.; Shapiro, N.I. Statin therapy is associated with decreased mortality in patients with infection. Acad. Emerg. Med., 2009, 16(3), 230-234.
15. Dobesh, P.P.; Klepser, D.G.; McGuire, T.R.; Morgan, C.W.; Olsen, K.M. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy, 2009, 29(6), 621-630.
16. Viasus, D.; Garcia-Vidal, C.; Gudiol, F.; Carratala, J. Statins for community-acquired pneumonia: current state of the science. Eur. J. Clin. Microbiol. Infect. Dis., 2010, 29(2), 143-152.
17. Mahboobi, S.K.; Shohat, E.Z.; Jellinek, S.P.; Rose, M. Systemic infections can decrease the threshold of statin-induced muscle injury. South Med. J., 2006, 99(4), 403-404.
18. Vincent, A.; Miller, J.A. Statins for sepsis: a cautionary note. Intensive Care Med., 2006, 32(5), 795.
19. Drage, S.M.; Barber, V.S.; Young, J.D. Statins and sepsis: panacea or Pandora's box? Lancet Infect Dis., 2007, 7(2), 80; author reply 80-81.
20. Golomb, B.A.; Evans, M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs, 2008, 8(6), 373-418.
21. Kopterides, P.; Falagas, M.E. Statins for sepsis: a critical and updated review. Clin. Microbiol. Infect., 2009, 15(4), 325-334.
22. Kadurugamuwa, J.L.; Sin, L.V.; Yu, J.; Francis, K.P.; Kimura, R.; Purchio, T.; Contag, P.R. Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob. Agents Chemother., 2003, 47(10), 3130-3137.
23. Akinbi, H.T.; Epaud, R.; Bhatt, H.; Weaver, T.E. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J. Immunol., 2000, 165(10), 5760-5766.
24. van der Poll, T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit. Care, 2008, 12(Suppl 6), S3.
25. Esmon, C.T. The protein C pathway. Chest, 2003, 124(3 Suppl), 26S-32S.
26. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; Fisher, C.J., Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 2001, 344(10), 699-709.
27. Castellino, F.J.; Ploplis, V.A. The protein C pathway and pathologic processes. J. Thromb. Haemost., 2009, 7(Suppl 1), 140-145.
28. Eto, M.; Kozai, T.; Cosentino, F.; Joch, H.; Luscher, T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation, 2002, 105(15), 1756-1759.
29. Aikawa, M.; Rabkin, E.; Sugiyama, S.; Voglic, S.J.; Fukumoto, Y.; Furukawa, Y.; Shiomi, M.; Schoen, F.J.; Libby, P. An HMG-CoAreductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001, 103(2), 276-283.
30. Jerwood, S.; Cohen, J. Unexpected antimicrobial effect of statins. J. Antimicrob. Chemother., 2008, 61(2), 362-364.
31. Chaudhry, M.Z.; Wang, J.H.; Blankson, S.; Redmond, H.P. Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg. Infect., (Larchmt) 2008, 9(2), 183-194.
32. Newman, T.B.; Hulley, S.B. Carcinogenicity of lipid-lowering drugs. JAMA, 1996, 275(1), 55-60.